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DISTROPHIN GENE MUTATION SPECTRUM IN CHILDREN WITH
DUCHENNE/BECKER PROGRESSING MUSCULAR DYSTROPHIES IN
UZBEKISTAN
Madzhidova Y.N., Omonova U.T.
Tashkent Pediatric Medical Institute
Abstract
Background. Duchenne and Becker progressing muscular dystrophies (D/BPMD) are
the one of the most common congenital diseases of the neuromuscular system of juniors in
the world. Along with the improvement in medical and genetic service and the quality of
prevention and early diagnosis of congenital and hereditary diseases, there are a number of
tasks that are pending, including medical and genetic counseling of hereditary diseases of the
neuromuscular system in children.
Methods. Direct DNA diagnostics was performed for 99 patients with D/BPMD from 86
families, 92 (92.9%) patients with DPMD, 7 (7.1%) patients with Becker PMD. The analysis
was carried out on 20 exons of the dystrophin gene — the promoter region, 3, 4, 6, 8, 13, 17,
19, 32, 42, 43, 44, 45, 47, 48, 50, 51, 52, 53, 60 exons. Indirect diagnosis was performed in 21
families weighed by D/BPMD using intragenic highly polymorphic markers located in the
45th (STR-45), 49th (STR-49), 50th (STR-50) gene introns. Mutations in 18 exons out of 20
studied were identified, which necessitates further study of the deletion spectrum of mutations
in the dystrophin gene in our population.
Results. In 35 patients (35.4%) of 32 families (37.2%), no deletions were detected, and in
64 patients (64.6%) of 54 families (62.8%), dystrophin gene deletions were detected with
various lengths - from one to nine exons: in 70.4% of families extended deletions were
verified (44 patients), deletions of one exon were found in 29.6% of families (20 patients). The
heterozygous genotype STR-45 (CA) 28 is highly informative in identifying heterozygous
carriers of the damaged dystrophin gene among relatives of the D/BPMD patient in
Uzbekistan.
Conclusion. There is huge demand for sequencing of a limited portion of the DMD gene
to determine the point mutation of 32 exon in the dystrophin gene. Furthermore, carrying out
prenatal diagnosis in high-risk families according to D/BPMD allowed to prevent the birth of
sick children and reduce disability among children for this disease.
Key words: progressive Duchenne and Becker myodystrophy, direct DNA diagnostics,
indirect DNA diagnostics, children.
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BACKGROUND
Duchenne and Becker progressive
muscular dystrophies (D/BPMD) are the
most common congenital diseases of the
neuromuscular system among children
(Arupova, 2016; and Basak et al, 2011).
According to experts of the World Health
Organization (WHO), the incidence of
DPMD is 1: 3500 and BPMD is 1: 20,000
live birth boys (Illarioshkin et al, 2002;
Gatta et al, 2015; and Zimowski et al, 2017).
Patients with Becker and Duchenne
muscular dystrophy have a mutation in the
DMD gene that leads to a deficiency or
absence of dystrophin protein. This results
in skeletal muscle weakness and loss of
ambulation, usually in the second decade of
life in Duchenne muscular dystrophy and
later in life in the milder Becker muscular
dystrophy. Both reduced and absent
dystrophin also leads to the development of
cardiomyopathy resulting in progressive left
ventricular dysfunction (cited in Soslow et
al, 2019).
Being aware of the clinical importance
of Becker and Duchenne muscular
dystrophy and cardiomyopathy has
increased during the last few decades. This
is mostly owing to progress in healthcare,
which have increased life expectancy in
patients with Duchenne muscular
dystrophy. The preponderance of Becker
and Duchenne research focuses on skeletal
muscle weakness, but cardiovascular disease
is now one of the leading causes of death in
patients with Duchenne muscular dystrophy
(Bach and Martinez, 2011). Identifying risk
factors leading to increased length of stay,
cost of hospitalization, and readmission
rates in this population can increase
recognition and potentially improve
outcomes in future admissions (Soslow et al,
2019).
Along with the development in the
Republic of Uzbekistan of a modern medical
and genetic service and improving the
quality of services in the field of prevention
and early diagnosis of congenital and
hereditary diseases, there are a number of
tasks that are pending, including medical
and genetic counseling of hereditary
diseases of the neuromuscular system in
children.
PURPOSE OF THE STUDY
To study the dystrophin gene mutation
spectrum in families of patients with
D/BPMD in Uzbekistan.
MATERIAL AND METHODS
The molecular-genetic part of this
research was carried out at the Department
of Molecular Medicine and Cellular
Technologies of Scientific Research
Institute of Hematology and Blood
Transfusion of the Ministry of Health of the
Republic of Uzbekistan.
STUDY POPULATION
Molecular genetic testing was carried
out using direct and indirect DNA
diagnostic methods. Direct DNA diagnostics
was carried out by detecting 20 frequent
deletions of the dystrophin gene in sick and
pregnant women from families weighed by
D/BPMD bearing a male fetus. Indirect
2
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DNA diagnostics was carried out with the
study of intragenic highly polymorphic
markers located in the 45th (STR-45), 49th
(STR-49), 50th (STR-50) introns of the gene
to determine the carriage of the mutant gene
among proband relatives. Direct DNA
diagnostics were performed for 99 patients
with D/BPMD from 86 families, 92 (92.9%)
patients with Duchenne PMD, 7 (7.1%)
patients with Becker PMD. The analysis was
carried out on 20 exons of the dystrophin
gene — the promoter region, 3, 4, 6, 8, 13,
17, 19, 32, 42, 43, 44, 45, 47, 48, 50, 51, 52,
53, 60 exons. Indirect diagnosis was
performed in 21 families weighed by
D/BPMD using intragenic highly
polymorphic markers located in the 45th
(STR-45), 49th (STR-49), 50th (STR-50)
gene introns.
Genomic DNA from peripheral blood
samples (Vacutainer Becton Dickinson
International with EDTA) was isolated using
the DIAtom ™ DNA PreplOO DNA
Isolation Kit, Molecular Genetics Center
LLC (Moscow) according to the
instructions. Amplification was performed
using GeneAmp PCR-system 2720 thermal
cyclers (Applied Biosystems, USA) using
DMD-del and DMD-CA kits (Center for
Molecular Genetics LLC, Moscow).
RESULTS
According to the results of molecular
diagnostics, in 35 patients (35.4%) of 32
families (37.2%), no deletions were
detected, and in 64 patients (64.6%) of 54
families (62.8%), dystrophin gene deletions
were detected with various lengths - from
one to nine exons: in 70.4% of families
extended deletions were verified (44
patients), deletions of one exon were found
in 29.6% of families (20 patients).
Mutations of the dystrophin gene found
in 4 families with related marriages were
characterized by deletions of one exon in the
distal region of the 3'-end (deletions of 48,
50 and 53 exons), and in 3 families
Duchenne muscular dystrophy was
determined for the first time in this
generation (Fig. 1). Mutations de novo in
our studies were found almost 2 times less
than in the detection of family cases of
diseases in the “hot spots” of the dystrophin
gene (32.6% versus 67.4%).
Fig. 1. The frequency of family marriages in families with D/BPMB
45
4
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1
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non-relative
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When analyzing deletions, deletions in
the distal part of the dystrophin gene were
most often detected, which accounted for
79.6% of all identified mutations in families:
50 exon in 24 cases, 51 exon in 22 cases, 52
exon in 16 cases, 48 exon in 17 cases, 53
exon - in 11 cases; 32 exon - 1; 42 exon - 1;
no deletions of the promoter zone and 60
exon were detected. With proximal
mutations, deletions of 19 (in 7 cases), 6 (in
7 cases), 4 (in 6 cases) and 17, 13, 8 in equal
amounts (in 5 cases, respectively) of exons
were more common (Fig. 2).
Fig. 2. The results of multiplex PCR diagnostics of the dystrophin gene on DNA
samples in 7 patients with D/BPMD.
In sporadic cases and familial forms, in
most cases deletions in the distal part of the
dystrophin gene — the 3'-end (deletion of
40-60 exons) were more often detected,
almost 3.6 times more often than the
frequency of occurrence of proximal
deletions of the dystrophin gene in 5'- end
(deletions of 3-19 exons) (Fig. 3).
Fig. 3. The ratio of de novo mutations and family cases of diseases according to the
“hot spots” of the dystrophin gene.
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Indirect DNA diagnostics using
intragenic highly polymorphic markers
located in the 45th (STR-45), 49th (STR-
49), 50th (STR-50) gene introns was
performed by 61 relatives from 21 families
burdened with D/BPMD. Of 21 families in
33.3% (7 families) when conducting direct
DNA diagnostics, deletions in the
dystrophin gene were not detected, in 14.3%
(3 families) deletions were detected at the 5'-
end, in 52.4% (11 families) - deletions were
detected at the 3'-end.
The linkage analysis of STR-45, STR-
49, and STR-50 loci with exon deletion of
the DMD gene was performed: a total of 26
healthy chromosomes without deletions (13
unrelated women) and 43 chromosomes of
patients with STR hemisygote deletion were
studied. A clear tendency was found to
increase the level of heterozygosity of
women according to STR-45, with the
presence of deletion of X chromosomes in
comparison with women with no deletion of
X chromosomes. The heterozygosity level
of STR-45 in the X chromosomes with no
deletion was 23.1%, and in the group with
deletion 41.9% (χ2 = 2.5; P = 0.1; OR = 2.4;
95% CI 0.8028-7.175). The difference in the
heterozygosity index for the STR-49 locus
in the X chromosomes with and without
deletion was significant and amounted to
34.9% and 11.5%, respectively (χ2 = 4.6; P
= 0.03; OR = 4.1 ; 95% CI 1,058-15,9). The
level of adhesion of heterozygotes at the
STR-49 locus to a deletion of exons of the
DMD gene was 4.1 times significantly
higher compared to heterozygotes of this
locus with no deletion. The frequency of the
STR 50 polymorphic locus in the X
chromosomes with and without deletion was
23.2% and 15.4%, respectively (χ2 = 0.6; P
= 0.4; OR = 1.7; 95% CI 0.464 -5.987).
Moreover, the difference in frequency in the
compared groups of X chromosomes was
not significant (Table 1).
Table 1
The frequency of distribution of exon deletion of the DMD and STR gene exons in
patient groups
Total informative results
for STR
STR 45 STR 49 STR 50 Total
X-chromosome with no
deletion
6 (23,1%) 3 (11,5%) 4 (15,4%) 26 chrom
X chromosomes with
deletion
18 (41,9%) 15 (34,9%) 10 (23,2%) 43 chrom
As can be seen from the table, a
tendency towards an increase in the level of
the heterozygous state in chromosomes with
the presence of distal mutations as compared
with proximal ones (χ2 = 1.8; p=0.2) was
revealed. Of the 12 women examined who
were carriers of the proximal mutation,
heterozygous and STR-45 homozygous
genes were identified in 7 (58.3%) and 5
(41.2%). The heterozygosity of the
5
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multiallelic STR-45, STR-49 and STR-50
loci in the subgroups of women with
proximal and distal deletions of the
dystrophin gene was 22.7% and 77.3%,
respectively.
To determine the level of information
content, i.e. heterozygosity of the
dinucleotide (CA)28 repeat of the STR-45
dystrophin gene, we studied 44 unrelated
healthy X chromosomes. The observed
heterozygosity frequency of this marker was
59.1% (0.59; 26/44) (Table 2).
For the heterozygous genotype of STR-
45 polymorphism, it was found that the
observed frequency of heterozygotes (Hobs)
is statistically significantly higher than the
expected Hexp calculated according to
Hardy-Weinberg law (0.59 versus 0.42%,
respectively, χ2 = 3.9; p = 0.049). The
deviation coefficient F of the actual
heterozygosity from the theoretical one was
+0.4.
For STR-45 (CA) 28, D was positive
and maintained >0. The Hobs value was close
to 0.6, which indicates a high level of
informational content of this microsophyllite
polymorphism for detecting heterozygous
carriage and prenatal DNA diagnostics in
high-risk D/BPMD families.
Table 2
Expected and observed frequencies of the distribution of genotypes by PXB of the
genetic marker STR-45 (CA)28
Genotype
Genotype frequency
χ2 Р
Observed Hobs Expected Hexp
-/- 0,41 0,5 0,34
0,049
-/+ 0,59 0,42 1,6
+/+ 0,00 0,09 1,92
Total 1,0 1,0 3,9
Microsatellite polymorphism repeats
(CA)24 and (AC)16 are located respectively
in introns 49 and 50 of the dystrophin gene.
These polymorphisms also have a certain
number of CA repeats (24 and 16,
respectively), inherited according to the
laws of Mendel. It was found that the STR-
49 (CA)24 polymorphism is in strong
disequilibrium in adhesion with STR-50
(AC)16, and therefore with the STR-45
(CA)28 microsatellite polymorphism, which
makes these markers useful when then of
these markers will not be informative.
In determining the level of
heterozygosity of these polymorphisms, 44
unrelated X chromosomes were also studied.
In both cases, the calculated actual
frequency of heterozygotes was 45.5%
(0.45; 10/22). Based on the obtained data,
the calculation of the level of theoretical
heterozygosity, i.e. the information content
of multiallelic systems in our studied
samples, according to the Hardy-Weinberg
6
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equation, amounted to - 0.35. As can be
seen, for both polymorphisms, the
theoretical number of heterozygotes is not
statistically significantly reduced compared
to the actual one (0.35 and 0.45,
respectively, χ2 = 1.9; p = 0.2). The relative
deviation of the actual heterozygosity from
the theoretical one turned out to be positive
and amounted to D = + 0.3.
DISCUSSIONS
The results of molecular genetic studies
have shown that family cases of Duchenne /
Becker PMD over the de novo mutation, as
well as extended deletions at the 3’-end of
the dystrophin gene, predominate in the
population sample of Uzbekistan. Deletions
of the gene were found in 64.6% of the
examined chromosomes, of which 21.9%
are located in the proximal part of the gene,
78.1% - in the distal part, which corresponds
to the data for the Russian and Kazakh
populations.
The heterozygosity of the multiallelic
loci STR-45 (CA)28, STR-49 (CA)24 and
STR-50 (CA)16 is a marker for detecting
carriers and prenatal DNA - the diagnosis of
Duchenne/Becker myopathies in high-risk
families. The calculated index of the total
theoretical heterozygosity of these loci was
0.71. This means that 71% of women in the
study sample are theoretically informative of
one of the three polymorphic markers for
indirect DNA diagnostics. However, in a
joint study of three multiallelic polymorphic
markers, the efficiency of detecting
heterozygous gene carriage among women
was 83.3%, while the difference between the
total expected and observed heterozygous
frequencies was statistically insignificant.
A positive correlative relationship was
revealed between the carriage of various
deletion mutations and the heterozygous
state of the polymorphic loci STR-45, STR-
49, and STR-50. The heterozygous genotype
STR-45 (CA)28 is highly informative in
identifying heterozygous carriers of the
damaged dystrophin gene in relatives of the
D/BPMD patient in Uzbekistan.
In the absence of frequent deletions
according to the results of direct and indirect
DNA diagnostics, the search for mutations
can be carried out by dystrophin gene
sequencing.
During the study, dystrophin gene
sequencing was performed on 2 D/BPMD
patients; the indication for sequencing was
the presence of clinical symptoms and
biochemical abnormalities of D/BPMD, as
well as primary muscle lesions according to
the results of EMG studies. Dystrophin gene
sequencing is a method for confirming the
diagnosis of D/BPMD in the presence of
clinical and laboratory signs of the disease
and negative results obtained using the
available methods of direct and indirect
DNA diagnostics.
Sequencing of the dystrophin gene in
the first case revealed the previously
described mutation - duplication of exons 3-
7 in the dystrophin gene in a hemizygous
state, leading to a shift in the reading frame,
which is typical for the clinical form of
DPMD disease. In the second case, the
previously undescribed mutation C.4518 +
2T>A was revealed in the dystrophin gene
7
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in the hemizygous state, leading to
replacements in the sites of donors of
splicing sites.
A prenatal invasive diagnosis of
D/BPMD was carried out on the basis of the
Republican Center “Screening for Mother
and Child” for 7 pregnant women who had a
male fetus from high-risk families for this
pathology. Of these, in 2 cases, fetal
biomaterial for further DNA research was
obtained by amniocentesis and
cordocentesis was performed in 5 cases.
According to the results of DNA
diagnostics, deletions in the dystrophin gene
with a high risk of clinical realization of the
disease after birth were identified in 3 cases
(42.8%) in the fetus, families were
recommended to terminate the pregnancy
for medical and genetic reasons. In the
remaining families, no dystrophin gene
mutations were detected in the fetuses, the
pregnancy was prolonged, and subsequently
a postnatal examination of the children was
performed to confirm the absence of
mutations in the dystrophin gene.
According to results of the research
conducted by LeRumeur (2015), therapies in
progress will not cure the DPMD disease but
slow down its progression. The purpose now
is to focus therapy on the BPMD-like
dystrophin sequences with the less severe
disease gene or exon skipping therapy. We
have now to increase our knowledge about
BPMD disease genetics and time course and
dystrophin structure consequences after
BPMD deletions. The diagnosis of BMD is
highly relevant to anticipate and to
understand data resulting from human
clinical trials. It is also likely that certain
severe patients should benefit from therapy
strategies or from compensatory strategies
elaborated for DPMD patients.
Cho et al (2017) analyzed the dystrophin
gene in 507 Korean D/BPMD patients by
multiple ligation-dependent probe
amplification and direct sequencing and
identified 117 different deletions, 48
duplications, and 90 pathogenic sequence
variations, including 30 novel variations.
Deletions and duplications accounted for
65.4% and 13.3% of Korean
dystrophinopathy, respectively, suggesting
that the incidence of large rearrangements in
dystrophin is similar among different ethnic
groups. We also detected sequence
variations in >100 probands. The small
variations were dispersed across the whole
gene, and 12.3% were nonsense mutations.
CONCLUSION
Thus, a positive correlative relationship
was revealed between the carriage of
various deletion mutations and the
heterozygous state of the polymorphic loci
STR-45, STR-49 and STR-50.  The
heterozygous genotype STR-45 (CA)28 is
highly informative in identifying
heterozygous carriers of the damaged
dystrophin gene among relatives of the
D/BPMD patient in Uzbekistan. Sequencing
of the dystrophin gene revealed a new
mutation C.4518 + 2T>A in the DMD gene
of chromosome X in the hemizygous state,
which indicates the need for sequencing of a
limited portion of the DMD gene to
determine the point mutation of 32 exon in
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the dystrophin gene. Furthermore, carrying
out prenatal diagnosis in high-risk families
according to D/BPMD allowed to prevent
the birth of sick children and reduce
disability among children for this disease.
STUDY LIMITATIONS
We could not perform sample size
calculation for this research and the number
of participants to prove the null hypothesis
might be less than it supposed to be. Thus,
further researches may be required with an
adequate sample size to show more clear
and exact results.
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